Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.2333.

IRWD has been the subject of several research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 1st. Finally, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th.

Insider Activity at Ironwood Pharmaceuticals

In other news, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the sale, the insider directly owned 313,680 shares of the company’s stock, valued at approximately $1,417,833.60. This represents a 28.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director directly owned 250,749 shares in the company, valued at $935,293.77. This trade represents a 7.92% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Pacer Advisors Inc. bought a new position in Ironwood Pharmaceuticals during the 1st quarter valued at $3,982,000. Segall Bryant & Hamill LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth $976,000. Bull Harbor Capital LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth $48,000. EverSource Wealth Advisors LLC raised its holdings in shares of Ironwood Pharmaceuticals by 48.7% in the first quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 6,656 shares during the last quarter. Finally, Quantinno Capital Management LP raised its holdings in shares of Ironwood Pharmaceuticals by 9.1% in the first quarter. Quantinno Capital Management LP now owns 129,703 shares of the biotechnology company’s stock valued at $455,000 after purchasing an additional 10,810 shares during the last quarter.

Ironwood Pharmaceuticals Stock Down 6.3%

IRWD stock opened at $3.56 on Thursday. The company has a market cap of $580.49 million, a PE ratio of 5.93 and a beta of 0.20. The business has a 50-day simple moving average of $3.84 and a 200 day simple moving average of $3.98. Ironwood Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. The firm had revenue of $106.51 million for the quarter, compared to analyst estimates of $92.11 million. On average, analysts anticipate that Ironwood Pharmaceuticals will post 1.04 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.